4//SEC Filing
Ellis Andrea 4
Accession 0000950170-25-105185
CIK 0001743881other
Filed
Aug 6, 8:00 PM ET
Accepted
Aug 7, 4:50 PM ET
Size
19.2 KB
Accession
0000950170-25-105185
Insider Transaction Report
Form 4
Ellis Andrea
Director
Transactions
- Exercise/Conversion
Common Stock
2025-08-05$16.75/sh+17,167$287,547→ 35,756 total - Sale
Common Stock
2025-08-05$49.00/sh−17,167$841,183→ 18,589 total - Exercise/Conversion
Stock Option (right to buy)
2025-08-05−17,167→ 34,334 totalExercise: $16.75Exp: 2033-06-21→ Common Stock (17,167 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.
- [F2]The option vests in three annual installments from June 21, 2024 through June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001877680
Filing Metadata
- Form type
- 4
- Filed
- Aug 6, 8:00 PM ET
- Accepted
- Aug 7, 4:50 PM ET
- Size
- 19.2 KB